Lisa Fichtel, MD
Medical Oncology · San Antonio, TXNPI 1932122348
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (48.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Novartis at 53.6% of the total. 2025 is the largest year on record at $1,512, more than ten times the $87 reported in 2019. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 60 payments — averaging $34.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Pfizer$132
- AstraZeneca$129
- E.r. Squibb & Sons, L.L.C.$106
- Bristol Myers Squibb$95
- Astellas Pharma US Inc$64
- plus $439 from 14 others
Across 2 payments — averaging $212.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$425
What the payments were for
- Food & beverage$98347%
- Education$975%
- Other$99748%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $1,113 |
| Pfizer | 5 | $132 |
| AstraZeneca | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Bristol Myers Squibb | 4 | $95 |
| Astellas Pharma US Inc | 3 | $64 |
| Taiho Oncology, Inc. | 2 | $60 |
| Puma Biotechnology, Inc. | 3 | $59 |
| Genentech USA, Inc. | 3 | $48 |
| AbbVie | 2 | $42 |
| Gilead | 2 | $38 |
| AVEO Pharmaceuticals, Inc. | 1 | $30 |
| Genmab U.S., Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Fennec Pharmaceuticals, Inc. | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Bayer | 1 | $15 |
How this compares
$2,078 in reported general payments places this provider in the 35th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 40 | $7,137 |
| Anastrozole | 183 | $2,422 |
| Dexamethasone | 35 | $988 |
| Tamoxifen Citrate | 15 | $496 |
| Letrozole | 30 | $484 |
| Gabapentin | 32 | $277 |
| Ondansetron OdtOndansetron | 41 | $248 |
| Ondansetron Hcl | 27 | $195 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $171 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in San Antonio
- Vijay GunugantiSan Antonio$1.5M
- Virginia KaklamaniSan Antonio$787K
- John SarantopoulosSan Antonio$588K
- Sukeshi AroraSan Antonio$188K
- Anthony TolcherSan Antonio$125K
- Zohra NooruddinSan Antonio$113K
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.